氯沙坦和缬沙坦治疗原发性高血压合并高尿酸血症的疗效比较

Comparison of Effects of Losartan and Valsartan on Essential Hypertension Complicating Hyperuricemia

目的观察比较氯沙坦和缬沙坦治疗原发性高血压合并高尿酸血症的降压和降尿酸作用。方法 60例原发性高血压伴高尿酸血症患者随机分为氯沙坦组和缬沙坦组,每组30例,分别服用氯沙坦50 mg·d-1和缬沙坦80 mg·d-1,4周后血压控制不佳者分别增加剂量至100 mg·d-1和160 mg·d-1,疗程8周。观察2组的血压和血尿酸变化。结果氯沙坦组和缬沙坦组均有良好的降压效果,降压疗效相似。氯沙坦组治疗后血尿酸水平与治疗前相比显著降低(P<0.05);缬沙坦组治疗前后血尿酸水平相比,差异无统计学意义。结论原发性高血压合并高尿酸血症者氯沙坦为首选降压药。

OBJECTIVE To evaluate the effect of losartan and valsartan on blood pressure and serum uric acid in patients with essential hypertension complicating hyperuricemia. METHODS Sixty patients with essential hypertension complicating hyperuricemia were randomized into losartan group（n=30） and valsartan group（n=30）. The losartan group was treated with 50 mg·d^-1 losartan and the valsartan group was treated with 80 mg·d^-1 valsartan for 8 weeks respectively. The dosages were added to 100 mg·d^-1 and 160 mg·d^-1 respectively from 4th week if the patients＇ blood pressures were not well controlled. The blood pressure and serum uric acid were compared between the two groups before and after treatment. RESULTS Losartan group and valsartan group both had nearly good effect on reducing blood pressure（P〉0.05）. Compared with prior treatment, serum uric acid after treatment in losartan group was decreased significantly（P〈0.05）, while in valsartan group it had no statistical significance（P〉0.05）. CONCLUSION Losartan is a better medication for patients with essential hypertension complicating hyperuricemia.